Bioequivalence and Bioavailability Forum

728 matches found.

• extra-reference design: no period effect assumption mittyri 2025-12-29 23:16 [RSABE / ABEL]
• extra-reference design: R code BEQool 2025-12-29 15:17 [RSABE / ABEL]
• extra-reference design: R code mittyri 2025-12-23 12:58 [RSABE / ABEL]
• extra-reference design BEQool 2025-12-22 19:27 [RSABE / ABEL]
• ICH M12 Drug Inter­action Studies: De­ter­mi­nation of No-Effect Boundaries BEQool 2025-11-26 12:58 [Regulatives / Guidelines]
• ICH M13A: Two-at-a-Time Helmut 2025-03-04 10:24 [Regulatives / Guidelines]
• "ranking" William designs mittyri 2025-02-19 22:08 [Design Issues]
• different ranks/levels of William design? Shuanghe 2025-02-12 01:46 [Design Issues]
• Questions about "sequence effect" mentioned in a FDA PSG Darborn 2024-12-10 12:04 [General Sta­tis­tics]
• OT: A choice between Helmut 2024-10-23 13:58 [Design Issues]
• Treatment-by-Group in PROC MIXED and PROC GLM? mittyri 2024-10-07 15:11 [General Sta­tis­tics]
• Treatment-by-Group in PROC MIXED and PROC GLM? BEQool 2024-10-07 12:27 [General Sta­tis­tics]
• Treatment-by-Group in PROC MIXED and PROC GLM? mittyri 2024-10-07 00:00 [General Sta­tis­tics]
• ANOVA of Model 1 BEQool 2024-10-03 18:08 [General Sta­tis­tics]
• ANOVA of Model 1 Helmut 2024-10-03 17:33 [General Sta­tis­tics]
• Group-by-Treatment Interaction: the final word? BEQool 2024-10-03 17:09 [General Sta­tis­tics]
• fixed or mixed effects model Helmut 2024-09-09 09:04 [BE/BA News]
• M13 Q&A Helmut 2024-09-06 10:31 [Regulatives / Guidelines]
• period within group and formulation Helmut 2024-08-06 00:29 [BE/BA News]
• period within group and formulation mittyri 2024-08-05 22:42 [BE/BA News]
• ICH M13A: Changes to Step 2 Helmut 2024-07-31 16:19 [BE/BA News]
• ICH M13A: Changes to Step 2 Helmut 2024-07-31 15:16 [BE/BA News]
• 🇦🇹 AGES Helmut 2024-07-24 13:16 [Regulatives / Guidelines]
• Standard deviation of different designs ElMaestro 2024-06-30 00:08 [General Sta­tis­tics]
• Partial replicate design: ABE Helmut 2024-06-27 10:00 [Regulatives / Guidelines]
• average bioequivalence Mahmoud 2024-06-24 13:29 [Regulatives / Guidelines]
• Phoenix Win­Non­lin: Variance estimate → CV, Welch-test Helmut 2024-05-30 11:21 [Software]
• crossover design when use ABEL with two test products Helmut 2024-02-23 10:25 [Design Issues]
• Subject effect justification Relaxation 2024-01-17 13:30 [General Sta­tis­tics]
• Subject effect justification Dafni_C 2024-01-17 11:00 [General Sta­tis­tics]
• Use all data and avoid the partial replicate design for the FDA Helmut 2023-12-07 10:01 [Design Issues]
• Outdated and wrong answers mittyri 2023-10-05 22:34 [General Sta­tis­tics]
• THX! Another attempt… Helmut 2023-07-08 14:15 [RSABE / ABEL]
• Likely wrong workaround? Helmut 2023-07-07 22:06 [RSABE / ABEL]
• Use the one for TRTR | RTRT Helmut 2023-07-06 10:46 [RSABE / ABEL]
• any SAS or R-macro for 3 period two sequence RSABEIs Achievwin 2023-07-05 20:38 [RSABE / ABEL]
• Requesting data for a publication 📥 ♻️ 🚀 Helmut 2023-02-23 11:46 [General Sta­tis­tics]
• Study Design: Two treatment or Four treatment Relaxation 2023-01-23 17:10 [Design Issues]
• CV limbo Helmut 2023-01-04 12:39 [Regulatives / Guidelines]
• Models, models! Helmut 2022-12-25 13:17 [General Sta­tis­tics]